Core Viewpoint - The acquisition of the Drug Production License by the subsidiary of Tuoxin Pharmaceutical marks a significant milestone, enabling the company to produce Coenzyme Q10 raw materials in compliance with industry regulations, which is expected to enhance its product structure and support long-term growth in the health sector [1] Group 1 - Tuoxin Pharmaceutical's wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained the Drug Production License from the Henan Provincial Drug Administration [1] - This is the first time Jingquan Biotechnology has received the Drug Production License, indicating that its products related to Coenzyme Q10 raw materials now meet the regulatory requirements for pharmaceutical production [1] - The acquisition of this license is anticipated to enrich and optimize the company's product structure, playing a crucial role in the development of its health business segment [1]
拓新药业：子公司取得药品生产许可证